Abstract
Castration-resistant prostate cancer is characterized by loss of the androgen inactivation enzyme HSD17B2, emphasizing the importance of intratumoral androgens in tumor progression. Inactive isoforms generated by alternative splicing destabilize the wild-type enzyme, adding steroidogenesis to other prostate cancer drivers that undergo oncogenic splicing, highlighting aberrant splicing as a therapeutic target. See related article by Gao et al., p. 1291
Funding Information
  • HHS | NIH | National Cancer Institute (NCI) (P50 CA97186)
  • HHS | NIH | National Cancer Institute (NCI) (P01 CA163227)
  • U.S. Department of Defense (DOD) (W81XWH-12-1-0208)